Genentech: PersevERA Breast Cancer Study Fails To Meet Primary Objective
Genentech, a member of the Roche Group (RO.SW,ROG.SW), announced results from the Phase III persevERA Breast Cancer study evaluating investigational giredestrant in combination with palbociclib for people with estrogen receptor-positive, human epidermal …